Concord Drugs Stock Price Analysis and Quick Research Report. Is Concord Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Concord Drugs. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Concord Drugs has a PE ratio of 209.50504801773 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Concord Drugs has ROA of 0.5148% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Concord Drugs has a Current ratio of 1.7032.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Concord Drugs has a ROE of 0.8706%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Concord Drugs has a Debt to Equity ratio of 0.4957 which means that the company has low proportion of debt in its capital.

• Sales growth: Concord Drugs has reported revenue growth of -14.629% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Concord Drugs for the current financial year is 10.1897807056734%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Concord Drugs is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Concord Drugs is Rs 0.4061. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Concord Drugs in Ticker for free. Also, one can get the intrinsic value of Concord Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Concord Drugs FAQs

Q1. What is Concord Drugs share price today?
Ans: The current share price of Concord Drugs is Rs 85.08.

Q2. What is the market capitalisation of Concord Drugs?
Ans: Concord Drugs has a market capitalisation of Rs 112.0929 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Concord Drugs?
Ans: The PE ratio of Concord Drugs is 209.50504801773 and the P/B ratio of Concord Drugs is 2.4397587770236, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Concord Drugs share?
Ans: The 52-week high share price of Concord Drugs is Rs 92.52, and the 52-week low share price of Concord Drugs is Rs 26.1.

Q5. Does Concord Drugs pay dividends?
Ans: Currently, Concord Drugs does not pay dividends. Dividend yield of Concord Drugs is around 0%.

Q6. What are the face value and book value of Concord Drugs shares?
Ans: The face value of Concord Drugs shares is Rs 10, while the book value per share of Concord Drugs is around Rs 34.8723. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Concord Drugs?
Ans: Concord Drugs has a total debt of Rs 16.911 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Concord Drugs?
Ans: The ROE of Concord Drugs is 0.8706% and ROCE of Concord Drugs is 4.73%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Concord Drugs a good buy for the long term?
Ans: The Concord Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Concord Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Concord Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Concord Drugs’s financials?
Ans: You can review Concord Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.